Clinical trials
Locally Advanced Head and Neck Carcinoma clinical trials
Below are recruiting locally advanced head and neck carcinoma clinical trials, each written for real people, not researchers. We’re tracking 192 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05286619RecruitingPhase 2
Pembrolizumab with chemotherapy for recurrent head and neck cancer
This trial studies whether pembrolizumab plus chemotherapy (platinum and gemcitabine) can control recurrent or metastatic head and neck squamous cell carcinoma that can’t be cured with local treatments. It may help shrink tumors and slow disease growth in people who haven’t had cancer medicines for this stage before.
Kuala LumpurAges 18 years+ - NCT05343325RecruitingPhase 2
Neoadjuvant low-dose radiation with chemo-immunotherapy for head and neck cancer
This Phase 2 study tests whether giving low-dose radiation before surgery—along with chemotherapy and an immunotherapy drug—can work better and be safe for treating locally advanced head and neck squamous cell cancer. It may help shrink tumors before surgery and reduce the chance of the cancer coming back.
Zhuhai, GuangdongAges 18–70 - NCT05420948RecruitingPhase 2
Pembrolizumab with chemotherapy for returning or spread head cancer
This Phase 2 study tests pembrolizumab (an immunotherapy) plus chemotherapy to treat head and neck cancer that has come back or spread. You might be eligible if standard local treatments won’t be curative and your tumor can be measured on scans.
Chicago, IllinoisAges 18 years+ - NCT05446467RecruitingPhase 2
Pembrolizumab before surgery for advanced head and neck cancer
This trial studies whether pembrolizumab, given before surgery, can improve outcomes for certain people with stage III–IVA head and neck squamous cell cancer. It’s typically added alongside low-dose PFAS as part of treatment leading up to standard surgery and afterward medicines/radiation.
Qingdao, ShandongAges 18–85 - NCT05473156RecruitingPhase 1/Phase 2
Study of AP203 for advanced solid tumors that grew despite treatment
This early-phase study tests AP203 (an investigational treatment) to see if it is safe and to look for signs it can shrink or control certain advanced cancers. The study includes a dose-finding part for many solid tumors, and a second part focused on specific lung and head/neck cancers that previously received PD-1/PD-L1 therapy.
TaipeiAges 18 years+ - NCT05668858RecruitingPhase 1/Phase 2
Test antibodies plus or minus chemo for advanced head and neck cancer
This early-phase study tests a combination of antibody medicines (with optional chemotherapy) in people with advanced or metastatic head and neck squamous cell carcinoma. The goal is to see how well the treatment controls the cancer and what side effects are like.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05758389RecruitingPhase 2
Immunotherapy plus chemo for locally advanced head and neck cancer
This Phase 2 study tests whether tislelizumab (an immunotherapy) combined with chemotherapy works better for locally advanced head and neck squamous cell cancer. It aims to improve cancer control when the tumor is large and has not spread to distant organs.
Nanjing, JiangsuAges 18–75 - NCT05854823Recruiting
Reduced radiation after surgery for advanced head and neck cancer
This trial looks at whether giving less (de-escalated) radiation after surgery is as effective and safer for people with locally advanced head and neck squamous cell carcinoma who had a strong response to treatment before surgery. If you had no remaining cancer or only very small amounts of cancer left in the surgical specimen, this approach may help reduce side effects while keeping control of the disease.
Zhuhai, GuangdongAges 18–70 - NCT05872880Recruiting
Oral cancer treatment with chemo, then surgery and radiation
This trial studies giving chemotherapy first, then removing the tumor with surgery and follow-up radiation for certain cases of oral squamous cell carcinoma. It may help shrink and control the cancer before and after surgery, depending on how well the tumor can be fully removed.
Changsha, HunanAges 18–65 - NCT05910827RecruitingPhase 1/Phase 2
Study of a HER3 antibody with cetuximab and possibly docetaxel
This Phase 1/2 trial tests whether an antibody that targets HER3 (with cetuximab, and possibly docetaxel) can help treat advanced squamous cell cancers that have already been treated or cannot use standard options. It mainly looks at safety first, and also whether the treatment can shrink tumors.
Sydney, New South WalesAges 18 years+ - NCT06064877RecruitingPhase 3
Study of ficlatuzumab plus cetuximab for advanced head and neck cancer
This trial tests a combination of two drugs, ficlatuzumab and cetuximab, for people with recurrent or metastatic head and neck cancer that is HPV-negative and has not responded to prior immunotherapy and chemotherapy. It aims to see if this combination can help shrink tumors or slow the disease.
Gilbert, ArizonaAges 18 years+ - NCT06100497RecruitingPhase 2
PD-1 plus chemo for advanced head and neck cancer
This trial tests a combination of immunotherapy (PD-1) and chemotherapy for people with advanced head and neck cancers that are poorly differentiated. The goal is to see if the combination helps shrink tumors before possible surgery or radiation.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06102395RecruitingPhase 3
Pembrolizumab plus chemo before surgery for advanced head and neck cancer
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy before surgery can help people with advanced head and neck cancer. It aims to see if the combination is more effective than chemotherapy alone.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Duarte, CaliforniaAges 18 years+ - NCT06194656RecruitingPhase 2
Trial of SIBP-03 for advanced head and neck cancer
This trial tests a new drug called SIBP-03 for people with head and neck squamous cell carcinoma that has come back or spread. It is for those whose cancer has worsened after prior immunotherapy and platinum chemotherapy, and who have no option for curative local treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06208826RecruitingPhase 2
Immunotherapy maintenance after surgery for head and neck cancer
This trial looks at whether continuing immunotherapy can help keep cancer from coming back in people with head and neck cancer who had a good response to chemo-immunotherapy before surgery. You would have already had surgery, and now the study tests a maintenance treatment to strengthen your immune system's fight against any remaining cancer cells.
Tianjin, Tianjin MunicipalityAges 18–80 - NCT06256588RecruitingPhase 3
Dostarlimab vs placebo after chemoradiation for head and neck cancer
This study tests whether the immunotherapy drug dostarlimab, given after standard chemoradiation, can keep advanced head and neck cancer from coming back. It is for people who have not had surgery and whose tumors are PD-L1 positive.
Jonesboro, ArkansasAges 18 years+ - NCT06258811RecruitingPhase 3
Chemo-immunotherapy before surgery for advanced mouth cancer
This trial tests whether giving chemotherapy plus immunotherapy before surgery can help treat advanced mouth cancer. It aims to shrink tumors and improve outcomes.
ShanghaiAges 18–75 - NCT06265285RecruitingPhase 2
Nivolumab at home vs. clinic for cancer treatment
This study compares giving the immunotherapy drug nivolumab as a shot under the skin at home versus in the clinic. It is for people with certain cancers who are already taking or starting nivolumab.
Jacksonville, FloridaAges 18 years+ - NCT07341737RecruitingPhase 1/Phase 2
SL-28 for advanced solid tumors that haven’t responded to treatment
This trial tests a new drug, SL-28, for people with advanced solid tumors that haven’t responded to or cannot be treated with standard therapies. It aims to find a safe dose and see if the drug can help shrink or slow the growth of your cancer.
Adelaide, South AustraliaAges 18 years+ - NCT06444009RecruitingPhase 2
Immunotherapy and chemo before surgery for head and neck cancer
This trial tests whether giving immunotherapy along with chemotherapy before surgery can help treat locally advanced head and neck cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
Chengdu, SichuanAges 18–75 - NCT07586124RecruitingPhase 2
Immunotherapy plus antibody drug for advanced head and neck cancer
This trial tests a combination of two drugs (pucotenlimab and becotatug vedotin) given before surgery for advanced head and neck squamous cell carcinoma. The goal is to shrink tumors and improve outcomes when combined with surgery.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07601737RecruitingPhase 2
Nimotuzumab with immunotherapy and chemotherapy for head and neck cancer
This trial tests a combination of three treatments—nimotuzumab (a targeted therapy), a PD-1 inhibitor (which boosts your immune system), and chemotherapy—followed by surgery for locally advanced head and neck squamous cell carcinoma. The goal is to shrink the tumor and improve survival.
ShanghaiAges 18–75 - NCT07178847Recruiting
Cancer DNA after chemoradiation for head and neck cancer
This study looks for cancer DNA left in the body after standard chemoradiation for advanced head and neck squamous cell cancer. It aims to understand if this residual DNA means the disease is more likely to come back.
Aurillac, CANTALAges 18–80
Hear when a new Locally Advanced Head and Neck Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced head and neck carcinoma?
- Yes. Clin2 currently lists 192 recruiting locally advanced head and neck carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced head and neck carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced head and neck carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- Advanced Head and Neck Squamous Cell Carcinoma
- Locally Advanced Head and Neck Cancer
- Locally Recurrent Head and Neck Squamous Cell Carcinoma
- Head and Neck Squamous Cell Carcinoma
- Head and Neck Carcinoma
- Recurrent Head and Neck Squamous Cell Carcinoma
- Metastatic Head and Neck Squamous Cell Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.